"Shingles"

Herpes zoster infection Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageHerpes zoster infection MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:30 Jul 2023Last updated:25 Aug 2023SummaryHerpes zoster (also known as shingles) typically presents with pain described as burning , MB, BS, FRCPA, FRCPathDifferentialsContact dermatitisHerpes simplexCholecystitisMore DifferentialsGuidelinesShingles (herpes zoster): the green book, chapter 28aRecommended immunization schedule for adults aged 19 years or older: United States, 2023More GuidelinesPatient leafletsChickenpoxShingles: what is it?More Patient leafletsLog in or subscribe to access all of BMJ Best PracticeUse

Shingles (herpes zoster) 1Shingles (herpes zoster)Chapter 28a: Shingles (herpes zoster)23 August 2021Shingles (herpes zoster)The diseaseShingles (herpes zoster) is caused by the reactivation of a latent varicella zoster virus (VZV) infection, generally decades after the primary infection. Primary VZV infection typically occurs during childhood and causes chickenpox (varicella); further definition for PHN. On average, PHN lasts from three to six months, but can persist for longer. The severity of pain can vary and may be constant, intermittent or triggered by stimulation of the affected area, such as by wind on the face. (Katz et al., 2004)Other complications of shingles depend on the nerves affected and include paresis (motor weakness), facial palsy and ‘herpes zoster ophthalmicus

Protective Effects of Recombinant Zoster Vaccine and Antiviral Therapy Against Cardiovascular Disease Following Herpes Zoster Infection. Herpes zoster (HZ) is associated with a higher risk of cardiovascular events, but the effect of the recombinant zoster vaccine (RZV) on this risk, alone or in combination with antiviral treatment, remains uncertain. The aim of this study was to evaluate

Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study. Rheumatoid arthritis (RA) patients have an increased risk of developing herpes zoster (HZ) compared to the general population. We aimed to measure health care utilization (HCU) and related costs of HZ from the public payer's perspective among RA patients. Adult RA

Herpes Zoster Infections With Multiple Sclerosis Disease-Modifying Therapies: A Real-World Pharmacovigilance Study. Immunosuppressive multiple sclerosis (MS) disease-modifying therapies (DMTs) may increase the risk of opportunistic infections such as herpes zoster (HZ). We sought to evaluate the risk of HZ across various MS DMTs using publicly available pharmacovigilance reporting data. We

Herpes Zoster (shingles) vaccination: Protocol for a health technology assessment Protocol for a health technology assessment (HTA) of herpes zoster vaccination for adults Health Information and Quality Authority Page 1 of 20 Herpes zoster vaccination for adults: Protocol for a health technology assessment Publication date: 12 December 2023 Protocol for a health technology Varicella-zoster virus is a herpes virus associated with two distinct clinical syndromes – varicella, commonly known as chickenpox and herpes zoster, commonly known as shingles. Primary infection results in varicella, after which the virus becomes latent and may reactivate after a period, typically several decades later, as herpes zoster. Herpes zoster is typically recognised by a painful blistering rash

Health technology assessment of Herpes Zoster (shingles) vaccination - I see is Health technology assessment of the addition of herpes zoster (shingles) vaccination to the adult vaccination programme Publication date: 19 July 2024 Health technology assessment of the addition of herpes zoster (shingles) vaccination to the adult vaccination programme Health Information and Quality Authority Page 2 experience surveys across a range of health and social care services, with the Department of Health and the HSE. Health technology assessment of the addition of herpes zoster (shingles) vaccination to the adult vaccination programme Health Information and Quality Authority Page 3 of 394 Table of contents Table of contents

Herpes zoster infection Herpes zoster infection - Symptoms, diagnosis and treatment | BMJ Best PracticeSkip to main contentSkip to search * About us * Help * Subscribe * Access through your institution * Log inBMJ Best Practice * Help * Getting started * FAQs * Contact us * Recent updates * Specialties * Calculators * Patient leaflets * Videos * Evidence * Drugs * Recent updates zoster. N Engl J Med. 2002 Aug 1;347(5):340-6.http://www.ncbi.nlm.nih.gov/pubmed/12151472?tool=bestpractice.com The pain typically precedes the rash by several days and can persist for several months after the rash resolves. The rash usually presents in a single dermatome and typically resolves within 4 to 5 weeks. A common complication is postherpetic pain.[2]Roxas M. Herpes zoster and postherpetic

Shingles (herpes zoster): the green book, chapter 28a Shingles (herpes zoster): the green book, chapter 28a - GOV.UK Skip to main content Cookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites to help us deliver account: sign in 1. Home 2. Health and social care 3. Public health 4. Health protection 5. Immunisation Guidance Shingles (herpes zoster): the green book, chapter 28a Shingles immunisation information for public health professionals.From: UK Health Security Agency Published 12 July 2013 Last updated 23 August 2021 — See all updates Get emails about this page DocumentsShingles: the green book

Diagnostic Methods and Management Strategies of Herpes Simplex and Herpes Zoster Infections. Herpesviruses are medium-sized double-stranded DNA viruses. Of more than 80 herpesviruses identified, only 9 human herpesviruses have been found to cause infection in humans. These include herpes simplex viruses 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus (VZV), human cyto-megalovirus (HCMV either asymptomatic shedding of virus or clinical manifestation of vesicular lesions. The clinical presentation is influenced by the portal of entry, the immune status of the host, and whether the infection is primary or recurrent. Affecting 60% to 95% of adults, herpesvirus-associated infections include gingivostomatitis, orofacial and genital herpes,and primary varicella and herpes zoster

Rare presentation of maxillary osteonecrosis and tooth exfoliation induced by herpes zoster infection in a 29-year-old Chinese male: a case report and literature review. We present a case of a 29-year-old male patient without immunodeficiency who suffered from rapid osteonecrosis and tooth exfoliation resulting from herpes zoster (HZ) infection in the left maxillary branch of the trigeminal nerve. Various complications associated with shingles infections have been reported, cases of osteonecrosis and tooth exfoliation due to HZ infection among young people without immunodeficiency are rare. In this case, we focus on the particular manifestation of HZ infection. The patient presented with clusters of erythema and papules, along with non-hemorrhagic blisters on the left face and the loss

Corticosteroids for Preventing Postherpetic Neuralgia After Herpes Zoster Infection HomeReviewsTherapy (NNT) ReviewsDiagnosis (LR) ReviewsAboutThe NNT, ExplainedThe NNT Rating SystemtheNNT Editorial ProcessThe NNT Intervention QuizAbout theNNT TeamSubmit an articleAccountLoginSign upContactDONATECorticosteroids for Preventing Postherpetic Neuralgia After Herpes Zoster InfectionNo benefit over placeboBenefits in NNTNone were helpedHarms in NNTNone were harmedView As: NNT %SourceHan Y, Zhang J, Chen N, He L, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2013;(3):CD005582.Study Population: 787 patients with herpes zoster (shingles) infection who were randomized to treatment with corticosteroid or placebo in five trialsEfficacy EndpointsPresence

Antiviral Medications for the Prevention of Postherpetic Neuralgia After Herpes Zoster Infection HomeReviewsTherapy (NNT) ReviewsDiagnosis (LR) ReviewsAboutThe NNT, ExplainedThe NNT Rating SystemtheNNT Editorial ProcessThe NNT Intervention QuizAbout theNNT TeamSubmit an articleAccountLoginSign upContactDONATEAntiviral Medications for the Prevention of Postherpetic Neuralgia After Herpes Zoster InfectionNo benefit over placeboBenefits in NNTNone were helpedHarms in NNTNone were harmedView As: NNT %SourceChen N, Li Q, Yang J, Zhou M, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2014;(2):CD006866.Study Population: 1,211 patients with herpes zoster (shingles) infection randomized to treatment with antiviral medication or placebo in six trialsEfficacy

Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report herpes zoster (HZ) incidence and risk factors in the tofacitinib UC clinical program (up to 7.8 years). Proportions and incidence rates (IRs; unique patients with events/100 patient-years) of HZ were evaluated in 4 cohorts: Induction (phase 2 and 3 induction study data), Maintenance (phase 3 maintenance study data), Overall (data from all phase 2, 3, and open-label, long-term extension studies), and Overall plus interim 6-month phase 3b and 4 data. Herpes zoster risk factors were assessed by Cox regression analysis. In the Induction and Maintenance Cohorts, IRs for HZ

Unusual subacute endocarditis following herpes zoster infection. a case report. This paper presents a rare case of subacute bacterial endocarditis (SBE) following a herpes zoster (HZ) episode, with no prior records found in the existing literature. Specifically, we describe a case of a 76-year-old female whose diagnosis of SBE was hindered by the concurrent manifestation of HZ symptoms, which

Increased Stroke Risk Following Herpes Zoster Infection and Protection With Zoster Vaccine. Studies evaluating stroke following varicella zoster virus (VZV) infection are limited, and the utility of zoster vaccination against this phenomenon is unclear. This study aimed to determine the risk of stroke 30 days following zoster infection and to evaluate the impact of zoster vaccinations ). Patients had a significantly higher risk of stroke within the first month following recent herpes zoster infection. Receipt of at least 1 zoster vaccination was found to mitigate this increased risk. Vaccination may therefore be viewed as a protective tool against the risk of neurologic postinfection sequelae.

Characteristics of herpes zoster infection in patients with COVID-19: a systematic scoping review. Although there is literature reporting correlations between varicella zoster virus (VZV) infections and COVID-19, insufficient evidence exists in this regard. This scoping review aims to identify the existing evidence regarding clinical characteristics of primary VZV infection or reactivation

Herpes zoster vaccine reduces chances of shingles after stem cell transplants Herpes zoster vaccine reduces chances of shingles after stem cell transplantsHerpes zoster vaccine reduces chances of shingles after stem cell transplants Skip to content * Accessibility options: * * Search articles Evidence * About Us * Browse content * Brain and Nerves * Birth Conditions * Blood * Cancer * Heart and FundingBibliographyMenu * About Us * Browse content * Become a reviewer * Newsletter Sign Up * Contact us * Homepage * > * Alert * > * Herpes zoster vaccine reduces chances of shingles after stem cell transplants Herpes zoster vaccine reduces chances of shingles after stem cell transplantsInfections 12.11.19 doi: 10.3310/signal-000835 View commentaries on this research This is a plain English summary of an original

Risk of severe herpes zoster infection in patients with polycystic kidney disease: A nation-wide cohort study with propensity score matching analysis. Polycystic kidney disease (PKD) is suggested to be likely associated with underlying immunological dysregulation. This lymphopenia poses a risk of viral infection. Data to elucidate the herpes virus infection risk in patients with PKD are lacking cohort. The index date was set as the date when the patients were newly diagnosed with PKD. All study patients were followed up until the occurrence of herpes zoster infection, death, withdrawal from the NHIRD for other reasons, or until December 31, 2013. We included 4366 PKD patients and 4366 non-PKD patients. The incidence rate and the risk of developing herpes zoster infection were estimated using

No Association Between DAA Treatment for HCV Infection and Herpes Zoster Infection in Analysis of Data From 37 Clinical Trials. Recent case series and retrospective studies have raised concerns that patients who receive direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection are at increased risk of developing varicella-zoster virus infection (VZV reactivation). We